百利天恒(688506.SH)：收到与百时美施贵宝就iza-bren项目里程碑付款2.5亿美元

Core Insights - SystImmune, a wholly-owned subsidiary of the company, has received a milestone payment of $250 million from Bristol-Myers Squibb (BMS) [1] - The company is eligible for up to an additional $250 million in near-term or contingent payments, as well as up to $7.1 billion in further payments upon achieving specific development, registration, and sales milestones [1] - The milestone payments outlined in the collaboration agreement are subject to certain conditions, and the final milestone payments remain uncertain [1]